Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer
- Authors
- Lee, J[Lee, Jeeyun]; Shergill, A[Shergill, Ardaman]; Park, H[Park, Haeseong]; Lee, KW[Lee, Keun-Wook]; Arkenau, HT[Arkenau, Hendrik-Tobias]; Kang, YK[Kang, Yoon-Koo]; Olowokure, OO[Olowokure, Olugbenga Olanrele]; Kim, JG[Kim, Jong Gwang]; Oh, SY[Oh, Sung Yong]; Oh, DY[Oh, Do-Youn]; Costin, D[Costin, Dan]; Pippas, AW[Pippas, Andrew William]; Chen, JS[Chen, Jen-Shi]; Chaney, MF[Chaney, Marya F.]; Koustenis, A[Koustenis, Andrew]; Youssoufian, H[Youssoufian, Hagop]; Makris, L[Makris, Lukas]; Culm, K[Culm, Kerry]; Mockbee, CM[Mockbee, Colleen M.]; Chau, I[Chau, Ian]
- Issue Date
- 1-Jun-2023
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.41, no.16
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 41
- Number
- 16
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.